Ruckus Wireless, Inc. provides carrier-class Wi-Fi solutions to service providers and enterprises worldwide. It provides gateways, controllers, and access points with related software and services. The company offers SmartCell Gateway, a carrier-class platform to support and manage its Smart Wi-Fi access points, as well as for the integration of Wi-Fi and other services into service provider network infrastructure; SmartCell access points that enables service providers to deploy networks within urban environments; and ZoneDirector Smart WLAN controllers that streamline the configuration and management of its access points. It also provides ZoneFlex access points, which support various virtual WLANs, Wi-Fi encryption, and advanced traffic handling, as well as ZoneFlex outdoor Smart Wi-Fi access points, and point-to-point and multipoint bridges. In addition, the company offers software products, such as FlexMaster, a software-based Wi-Fi management service platform for monitoring and administering networks, as well as technical support and maintenance services. It serves enterprise end-customers of mid-sized organizations in various industries, including hospitality; education; healthcare; warehousing and logistics; corporate enterprise; retail; state and local governments; and public venues, such as stadiums and convention centers, airports, and outdoor public areas, as well as serves a range of service providers comprising mobile operators, cable companies, wholesale operators, and fixed-line carriers. The company was formerly known as Video54 Technologies, Inc. Ruckus Wireless, Inc. was incorporated in 2002 and is headquartered in Sunnyvale, California.
VirnetX Holding Corporation develops software and technology solutions for securing real-time communications over the Internet. The company's software and technology solutions include secure domain name registry and GABRIEL Connection Technology that are designed to secure various real-time communications over the Internet, as well as enable organizations and individuals to establish communities of secure, registered users, and transmit information between various devices, networks, and operating systems. These secure network communities are designed to support content applications, such as Instant messaging, voice over Internet protocol, mobile services, streaming video, file transfer, remote desktop, and Mobile-to-Mobile communications in a secure environment. It also intends to provide a portfolio of licenses and services comprising VirnetX technology; GABRIEL Connection Technology software development kit, including object libraries, sample code, testing and quality assurance tools, and supporting documentation required by customers to implement the company's technology; domain name registrar service; registrar server software; connection server software; and relay server software, as well as technical support, and secure domain name master registry and connection services. The company serves developers and original equipment manufacturers of chips, servers, smart phones, tablets, e-Readers, laptops, net books, and other devices in the IP-telephony, mobility, fixed-mobile convergence, and unified communications markets. VirnetX Holding Corporation was incorporated in 2005 and is based in Zephyr Cove, Nevada.
Receptos, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics for immune disorders. Its lead product includes RPC1063, an oral sphingosine 1-phosphate 1 receptor modulator that is in Phase II portion of Phase II/III studies for the treatment of relapsing multiple sclerosis; and is in Phase II studies to treat ulcerative colitis. The company is also developing RPC4046, a monoclonal antibody, which is in Phase II studies for the treatment of eosinophilic esophagitis, an allergic/immune-mediated disorder. In addition, it is involved in a research program for glucagon-like peptide-1 receptor small molecule positive allosteric modulators that are in preclinical studies for the treatment of Type 2 diabetes. The company was formerly known as Receptor Pharmaceuticals, Inc. and changed its name to Receptos, Inc. in May 2009. Receptos, Inc. was founded in 2008 and is headquartered in San Diego, California.
TiVo Inc. provides software, services, and technology that enable the distribution and management of video content through set-top boxes (STBs), and smartphones and tablets primarily in the United States. It offers whole-home solutions that include 4-Tuner and 6-Tuner digital video recorders (DVRs)/gateways, IP STBs, and streaming to mobile and tablet iOS devices with features, such as What to Watch Now, Season Pass recordings, integrated search, access to broadband video content, TiVo online/mobile scheduling, and applications on tablet computers and smartphones. As of January 31, 2014, the company had 4.2 million subscriptions to the TiVo service through its TiVo-Owned and television service operators (MSO) businesses. It also provides short- and long-form interactive video advertising, lead generation, and commerce, as well as second-by-second audience research measurement solutions that combine television and Internet viewing data with purchase activity or demographic attributes; and engineering professional services in connection with the development and deployment of the TiVo service to its MSO customers. The company distributes TiVo DVR through consumer electronics retailers and its on-line store at TiVo.com; and offers TiVo service through agreements with satellite and cable television service providers and broadcasters on MSO provisioned STBs and other devices. The company was founded in 1997 and is headquartered in San Jose, California.
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops Orenitram, a prostacyclin analog for treatment of PAH; Ch14.18 MAb, an antibody for the treatment of neuroblastoma; Beraprost 314d, which is under Phase III clinical trials for the treatment of PAH; and PLacental eXpanded cells that are under Phase I trial for the treatment of PAH. Further, the company is involved in the pre-clinical stage development of glycobiology antiviral agents for the treatment of infectious diseases; UV-4B, an antiviral alpha-glucosidase inhibitor for the treatment of dengue; and engineered lungs and lung tissue that can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Science Applications International Corporation provides technical, engineering, and enterprise information technology (IT) services in the United States. Its technical and engineering solutions include engineering and maintenance of ground and maritime systems, logistics, training, and simulation, as well as operation and program support services. The company's enterprise IT solutions comprise end-to-end enterprise IT services, including the design, development, integration, deployment, management and operation, sustainment, and security of the clients IT infrastructure. It serves the U.S. Military comprising Army, Air Force, Navy, and Marines; the U.S. Defense Logistics Agency; the National Aeronautics and Space Administration; the U.S. Department of State; and the U.S. Department of Homeland Security. The company was formerly known as SAIC Gemini, Inc. and changed its name to Science Applications International Corporation in September 2013. Science Applications International Corporation was founded in 1969 and is headquartered in McLean, Virginia.
Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The company's lead drug candidate, Selinexor, a novel selective inhibitors of nuclear export (SINE) compound that specifically blocks XPO1 cargo binding is in Phase I clinical trials in patients with heavily pretreated relapsed and/or refractory hematological and solid tumor malignancies. Its other drug candidates comprise KPT-350 and related SINE compounds; PAK4 inhibitors; and Verdinexor, an oral SINE compound that is in Phase 2b clinical trials in pet dogs with newly-diagnosed or first relapse after chemotherapy lymphomas. The company was founded in 2008 and is based in Natick, Massachusetts.
Microsemi Corporation designs, manufactures, and markets analog and mixed-signal semiconductor solutions primarily in the United States, Europe, and Asia. Its products include radio frequency (RF) and power components, analog and RF integrated circuits, system-on-chip (SoC) solutions, timing and synchronization products, chip-scale atomic clocks, field programmable gate arrays (FPGAs), voice line circuits, security technology, and high-reliability ICs and discrete components. The company also offers subsystems and modules that include application-specific power modules, infrastructure time generation, distribution and synchronization systems, and Power-over-Ethernet (PoE) midspans. It primarily serves aerospace, communications, defense and security, and industrial markets. The company's products are used in wireless and wired LAN systems, communications infrastructure systems, pacemakers and defibrillators, missile systems, military and commercial satellites and aircrafts, oil field equipment, and airport security systems. Microsemi Corporation markets its products directly, as well as through electronic component distributors and independent sales representatives. The company was formerly known as Microsemiconductor Corporation and changed its name to Microsemi Corporation in February 1983. Microsemi Corporation was founded in 1960 and is headquartered in Aliso Viejo, California.
Revance Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic applications worldwide. Its lead product candidate is RT001, a topical gel formulation of botulinum toxin type A, which is in Phase III clinical trials for the treatment of crow's feet lines; has completed initial Phase II clinical trials for the treatment of hyperhidrosis and for the prevention of migraine headache; and has completed Phase I clinical trials for the treatment of other indications, such as neuropathic pain and rhinitis. The company is also developing RT002, a novel injectable formulation of botulinum toxin type A, which is being tested in the four-cohort Phase I/II clinical dose escalation trials for the treatment of glabellar lines. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.
RE/MAX Holdings, Inc. operates as a franchisor for residential and commercial real estate brokerage services in the United States and internationally. It operates in two segments, Real Estate Franchise Services, and Brokerage and Other. The company offers its real estate franchise services under the RE/MAX brand name. It also provides real estate brokerage services in the United States. The company was founded in 1973 and is headquartered in Denver, Colorado.